Group 1: Company Project Progress - The company has over 30 research and development projects, with global patent expirations concentrated between 2028 and 2033. Some products, such as Vabigatran and Rosuvastatin, are already in the registration submission stage [2] - The company plans to continuously add new product projects each year to create a tiered product structure. Additionally, its affiliate, Boya Biotech, focuses on high-difficulty specialty formulations, which may lead to business synergies [2] Group 2: Business Development - On February 4, 2026, the company announced that the raw material for Edoxaban passed the approval of the National Medical Products Administration (NMPA), which is expected to boost sales in the domestic market and synchronize with international market expansion [3] - The company is implementing a "first generic, one supply" strategy, with approved new products like Vildagliptin and Agomelatine set to join the domestic sales lineup and actively expand into emerging markets [3] Group 3: Business Status - Currently, domestic business revenue accounts for approximately 20% of total revenue. The company plans to bind with leading generic drug companies as main suppliers, with an average of 3-5 core customers per product, to further expand its domestic market share [4] - Seventeen technically mature new products are capable of global supply, and the company will rely on the early layout of the supply chain for products with upcoming patent expirations [4] Group 4: Company Situation - The company has recently obtained several invention patents, such as methods for catalyst regeneration, but has not disclosed specific timelines for industrialization [5] - As of the end of January 2026, there was a net outflow of main funds, but market sentiment changes should be observed in conjunction with subsequent performance and order fulfillment [5]

Financial Data and Key Metrics Changes - The company reported a 4% organic growth in the consumables business for the second quarter and expects sequential sales growth to average mid-single digits for the year [4][5] - The guidance for 2025 was updated, with the high end of the range adjusted from $425 million to $408 million due to the divestment of solutions and unexpected tariffs amounting to $30 million [41][42] Business Segment Data and Key Metrics Changes - The consumables business has compounded growth at 5% to 7% annually for over five years, driven by good clinical outcomes, brand inertia, and market share gains due to industry shortages [5][6] - The LVP (Large Volume Pump) revenue experienced double-digit growth, attributed to increased utilization and competitive wins, with a new product, Plum Duo, recently installed at customers [10][12] - The Vital Care segment saw a negative 4% organic growth in the second quarter, with expectations for flat sales in 2025 [33] Market Data and Key Metrics Changes - The overall market for infusion pumps has been abnormal, with significant catch-up growth due to actions taken by other manufacturers [10] - The competitive environment is shifting, with recalls and sales pauses affecting market dynamics, leading to a need for hospitals to decide on infusion pump platforms in the next 18 to 24 months [18][19] Company Strategy and Development Direction - The company is focused on maintaining competitive advantages through product innovation and integration of all pumps on a single platform, which enhances operational efficiency for customers [30] - The joint venture with Otsuka Pharmaceutical is seen as a strategic move to align with a leading innovator in the market, enhancing the company's product offerings without the capital intensity of traditional manufacturing [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the utilization rates across geographies, indicating a stable operating environment despite some challenges [3] - The company anticipates that the replacement cycle for its pump products will begin towards the end of next year, which could drive future revenue growth [16][17] Other Important Information - The company is navigating a complex regulatory environment, with ongoing scrutiny and multiple product approvals in the pipeline, which are critical for future growth [23][24] - Management highlighted the importance of not annualizing the impact of tariffs, as they are actively working on mitigating their effects through various strategies [56] Q&A Session Summary Question: What are the drivers of the consumables business growth? - Management identified good clinical outcomes, brand inertia, and market share gains from industry shortages as key drivers [5][6] Question: How does the company view the competitive environment for LVP? - Management noted that the competitive landscape is changing due to recalls and the need for hospitals to make decisions on infusion pump platforms [18][19] Question: What is the expectation for the approval of new devices? - Management expects a minimum of nine months for the approval of new devices, with ongoing efforts to streamline the process [26] Question: How does the company plan to address the Vital Care segment's performance? - Management indicated they are exploring the right solutions for the Vital Care segment, acknowledging its different growth rates compared to other segments [33][34] Question: What is the company's strategy for capital deployment once leverage ratios improve? - Management stated that they are focused on organic growth and do not feel pressured to pursue M&A, emphasizing the importance of R&D investments [61][62]

Financial Data and Key Metrics Changes - The company reported 4% organic growth in the consumables business for Q2 and expects mid-single digit sequential sales growth for the year [4][5] - The guidance for 2025 was updated, with the high end of the range adjusted from $425 million to $408 million due to tariffs and divestiture of the solutions business [42][43] Business Segment Data and Key Metrics Changes - The consumables business has compounded growth of 5% to 7% annually for over five years, driven by good clinical outcomes, brand inertia, and market share gains due to industry shortages [5][6] - The LVP (Large Volume Pump) revenue experienced double-digit growth, attributed to strong volume, competitive wins, and improvements in software and service [11][12] - The Vital Care segment saw a negative 4% organic growth in Q2, with expectations for flat sales in 2025 [34] Market Data and Key Metrics Changes - The infusion pump market has been abnormal for years, with current growth driven by catch-up from competitors and the company's competitive pipeline [11][19] - The competitive environment is influenced by recalls and sales pauses from other manufacturers, creating opportunities for market share gains [19][20] Company Strategy and Development Direction - The company is focused on integrating all pumps onto a single platform to enhance operational efficiency and customer experience [30][31] - The joint venture with Otsuka Pharmaceutical is seen as a strategic move to align with a leading innovator and improve product offerings in IV solutions [40][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the utilization rates across geographies, indicating a stable operating environment [3] - The company anticipates that the replacement cycle for pumps will begin towards the end of next year, which could drive future growth [17][18] Other Important Information - The company is navigating challenges related to tariffs, which are expected to impact gross margins by 200 to 300 basis points [49] - Management emphasized the importance of maintaining high regulatory standards in the infusion pump market, which they view as a competitive advantage [24] Q&A Session Summary Question: Why did the CEO buy back stock personally? - The CEO felt the market was missing the earnings opportunity and believed it was a good time to act [2] Question: What are the growth drivers for the consumables business? - Key drivers include good clinical outcomes, brand inertia, and market share gains from industry shortages [5][6] Question: How does the company view the competitive environment for LVP? - The company sees opportunities due to competitors facing recalls and the need for market remediation [19][20] Question: What is the expectation for the approval of new devices? - The company expects approvals for new devices like Plum Duo and Plum Solo within nine months [27] Question: How are tariffs impacting the financial outlook? - Tariffs are expected to have a $30 million impact, but the company is confident in mitigating some of these effects through cost-saving measures [43][45]